Accelerating vaccine development and deployment: report of a Royal Society satellite meeting
| Autor: | Brian Greenwood, Simon J. Draper, Migena Bregu, Adrian V. S. Hill |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Developing country
vaccine implementation General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine veterinary vaccines 030212 general & internal medicine 030304 developmental biology Licensure 0303 health sciences Government business.industry International health Timeline Articles human vaccines Public relations Vaccine efficacy 3. Good health vaccine development Software deployment New product development General Agricultural and Biological Sciences business |
| Zdroj: | Philosophical Transactions of the Royal Society B: Biological Sciences |
| ISSN: | 1471-2970 0962-8436 |
| DOI: | 10.1098/rstb.2011.0100 |
| Popis: | The Royal Society convened a meeting on the 17th and 18th November 2010 to review the current ways in which vaccines are developed and deployed, and to make recommendations as to how each of these processes might be accelerated. The meeting brought together academics, industry representatives, research sponsors, regulators, government advisors and representatives of international public health agencies from a broad geographical background. Discussions were held under Chatham House rules. High-throughput screening of new vaccine antigens and candidates was seen as a driving force for vaccine discovery. Multi-stakeholder, small-scale manufacturing facilities capable of rapid production of clinical grade vaccines are currently too few and need to be expanded. In both the human and veterinary areas, there is a need for tiered regulatory standards, differentially tailored for experimental and commercial vaccines, to allow accelerated vaccine efficacy testing. Improved cross-fertilization of knowledge between industry and academia, and between human and veterinary vaccine developers, could lead to more rapid application of promising approaches and technologies to new product development. Identification of best-practices and development of checklists for product development plans and implementation programmes were seen as low-cost opportunities to shorten the timeline for vaccine progression from the laboratory bench to the people who need it. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|